New Gram-positive antibiotics: Better than vancomycin?

Van Hal, Sebastiaan J. and Paterson, David L. (2011) New Gram-positive antibiotics: Better than vancomycin?. Current Opinion in Infectious Diseases, 24 6: 515-520. doi:10.1097/QCO.0b013e32834ab1de


Author Van Hal, Sebastiaan J.
Paterson, David L.
Title New Gram-positive antibiotics: Better than vancomycin?
Journal name Current Opinion in Infectious Diseases   Check publisher's open access policy
ISSN 0951-7375
1473-6527
Publication date 2011-12
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1097/QCO.0b013e32834ab1de
Volume 24
Issue 6
Start page 515
End page 520
Total pages 6
Place of publication Philadelphia, PA, United States
Publisher Lippincott Williams & Wilkins
Collection year 2012
Language eng
Formatted abstract
Purpose of review: Despite concerns about vancomycin use in the treatment of multidrug-resistant Gram positives, evidence for better therapeutic outcomes with alternative antibiotics is lacking. This review focuses on recent advances.
Recent findings: Combination therapy with vancomycin–rifampin, although associated with better cure rates, resulted in the emergence of high rates of rifampin resistance. Of the newer anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics, ceftopibrole, ortivancin and dalbavancin require further development prior to a further assessment by the United States Food and Drug Administration. Ceftaroline, telavancin and daptomycin were associated with comparable clinical cure rates compared with vancomycin in the treatment of complicated MRSA skin and soft tissue infections. In the treatment of hospital-acquired pneumonia, both telavancin and linezolid resulted in significantly greater clinical cure rates compared with vancomycin. Despite greater clinical cure rates, no difference in overall or infection-related mortality was detected. Of concern is the appearance of daptomycin and linezolid resistance following increased use. Toxicity profiles (especially of linezolid) are comparable to vancomycin provided short-duration therapy is prescribed. The first reports of daptomycin-induced acute eosinophillic pneumonia were described in 2010.
Summary: Based on current evidence, greater microbiological and clinical cure rates are achieved with alternative agents. However, these differences do not translate into mortality benefits compared with vancomycin for the treatment of S. aureus infections.
Keyword Antibiotic therapy
Gram positive
Methicillin-resistant Staphylococcus aureus
Multidrug resistant
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: UQ Centre for Clinical Research Publications
Official 2012 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 20 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 27 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 20 Nov 2011, 05:01:47 EST by System User on behalf of UQ Centre for Clinical Research